Myeloid Malignancies

Pipeline Programs

Companies

Clinical Trials

Approved Products

Pipeline by Development Stage

Preclinical

Phase 1

Phase 1/2

Phase 2

Phase 2/3

Phase 3

On Market

Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Monoclonal Antibody

2100%

+ 2 programs with unclassified modality

Competitive Landscape

4 companies ranked by most advanced pipeline stage

Pre

P1/2

P2/3

Mkt

AgilentBelgium - Diegem

1 program

DUK-CPG-001Phase 21 trial

Active Trials

NCT02452697Unknown36Est. Oct 2024

Kite PharmaCA - El Segundo

1 program

MagrolimabPhase 2Monoclonal Antibody1 trial

Active Trials

NCT04778410Terminated54Est. Mar 2024

Kymera TherapeuticsMA - Watertown

1 program

KT-253Phase 11 trial

Active Trials

NCT05775406Completed52Est. Dec 2024

Gilead SciencesFOSTER CITY, CA

1 program

MagrolimabPHASE_2Monoclonal Antibody

Trial Timeline

Clinical trial activity over time

2021

2022

2023

2024

2025

2026

Kite PharmaMagrolimab

AgilentDUK-CPG-001

Kymera TherapeuticsKT-253

Clinical Trials (3)

Total enrollment: 142 patients across 3 trials

NCT04778410 Kite PharmaMagrolimab

Study of Magrolimab Combinations in Participants With Myeloid Malignancies

Start: Jun 2021Est. completion: Mar 202454 patients

Phase 2Terminated

NCT02452697 AgilentDUK-CPG-001

Ph2 NK Cell Enriched DCIs w/wo RLR9 Agonist, DUK-CPG-001 From Donors Following Allogeneic SCT

Start: Jun 2016Est. completion: Oct 202436 patients

Phase 2Unknown

NCT05775406 Kymera TherapeuticsKT-253

Safety and Clinical Activity of KT-253 in Adult Patients with High Grade Myeloid Malignancies, Acute Lymphocytic Leukemia, Lymphoma, Solid Tumors

Start: May 2023Est. completion: Dec 202452 patients

Phase 1Completed

Phase Legend

Preclinical— Lab & animal studies

Phase 1— Safety & dosing

Phase 2— Efficacy testing

Phase 3— Large-scale trials

On Market— Approved & available

Key Insights

Monoclonal Antibody is the dominant modality (100% of programs)

4 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.